Silence Therapeutics Q1 2025 Update
Ticker: SLNCF · Form: 10-Q · Filed: May 8, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, collaboration, financials
TL;DR
**Silence Therapeutics Q1 2025: Financials and R&D updates filed. Key collaborations with Mallinckrodt & AstraZeneca.**
AI Summary
Silence Therapeutics plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial data includes information on common stock, additional paid-in capital, and retained earnings as of March 31, 2025, and December 31, 2024. The company also reported on research collaboration income, including a specific collaboration with Mallinckrodt Plc during Q1 2024 and Q1 2025, and a collaboration agreement with AstraZeneca.
Why It Matters
This filing provides investors with a quarterly financial snapshot and insights into Silence Therapeutics' ongoing research collaborations, which are crucial for its drug development pipeline.
Risk Assessment
Risk Level: medium — Biotech companies like Silence Therapeutics are inherently risky due to the long and uncertain drug development process, regulatory hurdles, and reliance on successful collaborations.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Latest financial data available)
- 2024-12-31 — Prior Period End Date (Comparison point for financial changes)
Key Players & Entities
- Silence Therapeutics plc (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- December 31, 2024 (date) — Previous reporting period end
- Mallinckrodt Plc (company) — Partner in research collaboration
- AstraZeneca (company) — Partner in collaboration agreement
FAQ
What was the research collaboration income from Mallinckrodt Plc in Q1 2025?
The filing indicates research collaboration income from Mallinckrodt Plc for the period January 1, 2025, to March 31, 2025.
What is the company's financial position regarding Additional Paid-In Capital as of March 31, 2025?
The filing includes data for us-gaap:AdditionalPaidInCapitalMember for the period January 1, 2025, to March 31, 2025.
Were there any stock options exercised during Q1 2025?
Yes, the filing references sln:OptionsExercisedOneMember for the period January 1, 2025, to March 31, 2025, and sln:AmericanDepositaryShareADSMember with sln:OptionsExercisedThreeMember as of March 31, 2025.
What is the company's retained earnings as of March 31, 2025?
The filing references us-gaap:RetainedEarningsMember for the period ending March 31, 2025.
What was the nature of the collaboration with AstraZeneca?
The filing mentions a sln:CollaborationAgreementWithAstrazenecaMember for the period January 1, 2024, to March 31, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Silence Therapeutics plc (SLNCF).